A succinct status report on ADT

In all of 3 pages, Dr. Mohler does a great job in summarizing the current status around the use of ADT. […ADT plus radiation therapy should be used in patients at high risk, intermittent ADT is more appropriate for most patients than continuous ADT, and docetaxel should be given with ADT for high-volume metastatic disease.”] But he also comments on treatments other than the LHRH drugs. He mentions that non-oral estrogens can provide the same cancer control as the LHRH agents “and seem safer”. Lastly, he points out that compared to LHRH drugs, orchiectomy has been recently shown to have a “lower risk of fracture, peripheral arterial disease, and cardiac-related complications, and a similar risk of diabetes, thromboembolism, and cognitive decline.


Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, Zhao D, Niu Y. 2016. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer 16(1):180. www.ncbi.nlm.nih.gov/pubmed/26940836